<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617498</article-id><article-id pub-id-type="pmc">5873787</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0145</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Long-Term Results of Mitral Valve Repair</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>da Costa</surname><given-names>Francisco Diniz Affonso</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Colatusso</surname><given-names>Daniele de F&#x000e1;tima Fornazari</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, MSc</role></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Gustavo Luis do Santos</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Parra</surname><given-names>Kallyne Carolina Silva</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Botta</surname><given-names>Mariana Cozer</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Balbi Filho</surname><given-names>Eduardo Mendel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Veloso</surname><given-names>Myrian</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Miotto</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Andreia Dumsch de Aragon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, MSc</role></contrib><contrib contrib-type="author"><name><surname>Colatusso</surname><given-names>Claudinei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, MSc</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Pontif&#x000ed;cia Universidade Cat&#x000f3;lica do Paran&#x000e1;
(PUC-PR), Curitiba, PR, Brazil. </aff><aff id="aff2">
<label>2</label> Department of Cardiac Surgery, Instituto de Neurologia e
Cardiologia de Curitiba (INC-Cardio), Curitiba, PR, Brazil. </aff><author-notes><corresp id="c1">Correspondence Address: Francisco Diniz Affonso da Costa, Rua
Jeremias Maciel Perretto, 300 - Campo Comprido - Curitiba, PR, Brazil, Zip code:
81210-310. E-mail: <email>fcosta13@me.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage><history><date date-type="received"><day>24</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>7</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Current guidelines state that patients with severe mitral regurgitation
should be treated in reference centers with a high reparability rate, low
mortality rate, and durable results.</p></sec><sec><title>Objective</title><p>To analyze our global experience with the treatment of organic mitral
regurgitation from various etiologies operated in a single center.</p></sec><sec><title>Methods</title><p>We evaluated all surgically treated patients with organic mitral
regurgitation from 2004-2017. Patients were evaluated clinically and by
echocardiography every year. We determined early and late survival rates,
valve related events and freedom from recurrent mitral regurgitation and
tricuspid regurgitation. Valve failure was defined as any mitral
regurgitation &#x02265; moderate degree or the need for reoperation for any
reason.</p></sec><sec><title>Results</title><p>Out of 133 patients with organic mitral regurgitation, 125 (93.9%) were
submitted to valve repair. Mean age was 57&#x000b1;15 years and 52 patients
were males. The most common etiologies were degenerative disease (73
patients) and rheumatic disease (34 patients). Early mortality was 2.4% and
late survival was 84.3% at 10 years, which are similar to the age- and
gender-matched general population. Only two patients developed severe mitral
regurgitation, and both were reoperated (95.6% at 10 years). Freedom from
mitral valve failure was 84.5% at 10 years, with no difference between
degenerative and rheumatic valves. Overall, late &#x02265; moderate tricuspid
regurgitation was present in 34% of the patients, being more common in the
rheumatic ones. The use of tricuspid annuloplasty abolished this
complication.</p></sec><sec><title>Conclusion</title><p>We have demonstrated that mitral regurgitation due to organic mitral valve
disease from various etiologies can be surgically treated with a high repair
rate, low early mortality and long-term survival that are comparable to the
matched general population. Concomitant treatment of atrial fibrillation and
tricuspid valve may be important adjuncts to optimize long-term results.</p></sec></abstract><kwd-group><kwd>Mitral Valve</kwd><kwd>Mitral Valve Insufficiency</kwd><kwd>Mitral Valve Prolapse</kwd><kwd>Mitral Valve Annuloplasty</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="43%" span="1"/><col width="3%" span="1"/><col width="5%" span="1"/><col width="43%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= American College of
Cardiology</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Myxomatous
degeneration</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mitral
regurgitation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
replacement</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mitral valve repair</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Right atrial</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence
intervals</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Rheumatic disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COPD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic obstructive
pulmonary disease</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Right ventricular</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SAM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Systolic anterior
motion</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DDLV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diastolic dimension of
the left ventricle</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Extended extracorporeal
circulation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SDLV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Systolic dimension of
the left ventricle</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Fibroelastic
deficiency</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SIH/SUS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hospital Information
System - Ministry of Health</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hazard ratios</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">STS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society of Thoracic
Surgeons</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">INC-Cardio</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Instituto de Neurologia
e Cardiologia de Curitiba</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TEE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transesophageal
echocardiography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Tricuspid
regurgitation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">USA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= United States of
America</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Mitral valve repair (MVR) is considered the best surgical option for most patients
with severe mitral regurgitation (MR), including elderly patients with associated
comorbidities and higher operative risks<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. In fact,
recent guidelines for management of valvular heart diseases indicate that
asymptomatic patients with preserved left ventricular function should be redirected
to "reference centers" and surgery should be considered only when the probability of
the repair is high, and the operative mortality is low<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>The Society of Thoracic Surgeons (STS) database demonstrates that despite an
increasing adoption of conservative operations in the last decade, the overall rate
of MVR in the United States of America (USA) is still only around 70%, and probably
restricted to simpler repairs involving prolapse of the posterior cusp, in most
centers<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.
In Brazil, MVR is performed even more infrequently, and although the statistical
estimates are somewhat imprecise, the incidence of MVR appears to be in a
disappointingly range of 1520% (Hospital Information System - Ministry of Health
[SIH/SUS]).</p><p>Our surgical group, working in two different institutions, has been involved in
mitral valve repair since the late 1980's. The Instituto de Neurologia e Cardiologia
de Curitiba (INC-Cardio) is a new private health institution in Curitiba, and since
its inception in 2004, we have had the opportunity to establish a heart valve team
that enabled us not only to perform all valvular operations with intraoperative
transesophageal echocardiography (TEE) control, but also to prospectively follow our
patients at ambulatory level in an adequate manner. The aim of this study was to
analyze our global experience with all surgically treated patients presented with
any form of organic mitral valve insufficiency at this institution.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This study was approved by the Institutional Research Ethical Committee (number
1.061.245) and registered at Plataforma Brasil (number CAAE 42.708015.2.0000.5227).
We retrospectively analyzed all patients operated at INC-Cardio from January 2004 to
March 2017 who had the diagnosis of organic MR as the primary indication for
surgery. Patients with concomitant procedures such as tricuspid repair, ablation for
atrial fibrillation (AF), and coronary artery bypass grafting (CABG) were included.
However, patients with concomitant aortic valve replacement (AVR) or functional MR
due to ischemic cardiomyopathy were excluded from the analysis.</p><p>The etiology of the disease was based in echocardiographic findings and confirmed at
the operation by visual inspection. Patients with degenerative disease were
subdivided in fibroelastic deficiency (FD), moderate myxomatous degeneration (MD),
and Barlow disease, according to the degree of myxomatous changes. Typically,
patients with normally sized and thin cusps, except for the prolapsing segment, were
considered FD; while those with voluminous, aneurysmal and thickened cusps, with
massive annular dilatation and often displaced posterior cusp attachment, were
categorized as Barlow disease. Valves with intermediary changes in this spectrum
were labeled as MD. Rheumatic disease (RD) patients were included if they had pure
MR or mixed lesions with at least moderate degree of MR.</p><sec><title>Surgical Technique</title><p>All operations were performed by a single surgeon (FDAC), most commonly through
full sternotomy or, in the last few years, using a right minithoracotomy
approach in selected cases. When midline sternotomy was used, cardiopulmonary
bypass (CPB) was instituted with central aortic and bicaval cannulation. We
routinely employed moderate systemic hypothermia (32&#x000ba;C), and myocardial
protection was obtained with intermittent antegrade cold blood cardioplegia. For
the minithoracotomy cases, CPB was instituted with peripheral arterial and
venous femoral cannulation, and cardioplegia was performed with a single dose of
Custodiol solution<sup>&#x000ae;</sup>.</p><p>After gaining exposure of the mitral valve through a left atriotomy parallel to
the interatrial groove, careful and systematic valve analysis was performed to
identify all valve lesions producing valve dysfunction. Posterior leaflet
prolapses were treated either by triangular or quadrangular resection of the
prolapsing segments or by the insertion of neo-chords utilizing the "respect"
concept. Whenever there was excess of posterior leaflet tissue, a sliding plasty
was performed to reduce the height of the posterior leaflet in order to avoid
systolic anterior motion (SAM). Anterior leaflet prolapse was preferentially
corrected with the utilization of Gore-Tex neo-chords, but we also used the
flipover technique or papillary muscle repositioning in some cases. In rheumatic
cases, shaving and thinning of the leaflets as well as resection of scarred and
fused primary and secondary chords were often necessary to increase leaflet
mobility. Cusp extension of the anterior leaflet was utilized to increase
surface coaptation in some cases. Mild or moderate areas of calcifications were
fully debrided. In the presence of active bacterial endocarditis, all infected
tissues were excised, and the resultant defects were corrected with patches of
decellularized human pericardia.</p><p>Except for patients with acute endocarditis, a Carpentier-Edwards Physio II
annuloplasty ring<sup>&#x000ae;</sup> (Edwards Lifesciences LLC, Irvine, CA, USA)
or a posterior bovine pericardium band<sup>&#x000ae;</sup> (Cardiopr&#x000f3;tese
Ltda, Curitiba, PR, Brazil) was employed to correct annular dilatation and to
stabilize the repair. Valve competence was tested with saline solution or by
pressurizing the left ventricle (LV) with blood through a cardioplegia line
inserted in the apex of the LV. Tricuspid annulus dilatation with or without
regurgitation (TR) was corrected with Carpentier-Edwards Tricuspid Physio
ring<sup>&#x000ae;</sup> (Edwards Lifesciences, Irvine, CA, USA) and CABG was
performed with standard techniques. To ascertain an adequate repair,
intraoperative TEE was performed in all patients after weaning from CPB.</p></sec><sec><title>Patient Data and Clinical Follow-up</title><p>Preoperative clinical data were obtained by reviewing hospital charts and
operative notes. Early mortality was defined as any death occurring before
hospital discharge or during the first 30 postoperative days. Causes of early
and late deaths were determined by hospital charts review, death certificates,
information from the physician who was caring for the patient at that time or
communication with the patient's family. Early and late postoperative
complications were reported according to well-established
guidelines<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Clinical follow-up was obtained at one, six, and 12 months after the operation
and then annually thereafter in our outpatient clinic, with the referring
cardiologist or by direct contact with the patient or his/her family. For this
study, a database freeze was performed in March 2017. Clinical follow-up was
obtained within two years of closure in 95% of the patients (five patients were
lost to follow-up). Anticoagulation with sodium warfarin was indicated only to
patients with AF, to those who had AF ablation or after an episode of cerebral
embolism. Patients with RD were oriented to have lifelong oral penicillin as a
secondary prophylaxis against rheumatic fever.</p></sec><sec><title>Echocardiographic Analysis</title><p>Mitral valve function was evaluated by transthoracic twodimensional Doppler
echocardiography, performed by the referring cardiologist or at our outpatient
clinic at yearly intervals. Whenever it was necessary, supplemental information
was obtained with 2D or 3D TEE studies.</p><p>All patients were operated with intraoperative TEE control, including 3D real
time images in the last two years.</p><p>MR was initially classified as none, trivial, mild, moderate, and severe, based
on the length and area of the regurgitant jet and using American Society of
Echocardiography's guidelines<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Valve failure was defined as recurrent
significant regurgitation of more than 1+ MR (mild MR) or mitral valve
reoperation.</p></sec><sec><title>Statistical Analysis</title><p>Statistical analysis was conducted with The R Project for Statistical Computing
statistical software (<ext-link ext-link-type="uri" xlink:href="www.cran.r-project.org/www.graphpad.com/guides/prism/7/http://www.ibge.gov.br">www.cran.r-project.org/</ext-link> version 3.3.1) and Graph Pad Prism
Software (<ext-link ext-link-type="uri" xlink:href="www.cran.r-project.org/www.graphpad.com/guides/prism/7/http://www.ibge.gov.br">www.graphpad.com/guides/prism/7/</ext-link>). Data were presented as
frequencies or means with standard deviations. The Kaplan-Meier method was used
to estimate survival and freedom from morbid events, and results were considered
meaningful up to 10 years. For outcomes other than death, patients were right
censored in case of a late death. Age- and sex-matched Brazil general population
survival estimates for the year 2013 (median year of surgery of the study
cohort) were obtained from data published by the Instituto Brasileiro de
Geografia e Estat&#x000ed;stica (<ext-link ext-link-type="uri" xlink:href="www.cran.r-project.org/www.graphpad.com/guides/prism/7/http://www.ibge.gov.br">http://www.ibge.gov.br</ext-link>), and statistical comparison with
survival rates from the study cohort was done using a one-sample log-rank
test.</p><p>Univariable analysis was carried out with chi-square tests and log-rank test to
determine the risk factors for reoperation and valve failure, and they were
considered significant when <italic>P</italic>&#x0003c;0.05. Predictors were
expressed by their hazard ratios (HR) with 95% confidence intervals (CI).
Variables tested included patient's age, gender, New York Heart Association
(NYHA) functional class, etiology, AF, systemic arterial hypertension, chronic
obstructive pulmonary disease (COPD), diabetes, smoking, renal failure, coronary
artery disease (CAD), previous cardiac operations, concomitant procedures,
cross-clamp, and extended extracorporeal circulation (ECC) times.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>From January 2004 to March 2017, our surgical group has performed 538 MVR, of which
125 were done at INC-Cardio and are the subject of this study. During this period,
133 patients were operated with a diagnosis of organic MR, and only eight (acute
endocarditis = 3, advanced mitral mixed lesions = 3, and failed previous MVR done
elsewhere = 2) had a mitral valve replacement, yielding an overall 93.9% global
repair rate. All patients (100%) with degenerative mitral valve disease undergoing a
first operation had a MVR.</p><p>The demographics of the 125 MVR patients are summarized in <xref ref-type="table" rid="t1">Table 1</xref>. Mean patient age was 57&#x000b1;15 years (range: 9 - 87
years), 52 (42%) patients were males, and 23 (18%) were older than 70 years. The
most common etiology was degenerative disease in 73 (58%) patients, followed by RD
in 34 (27%). Preoperatively, 44 (35%) patients were in NYHA functional class III and
IV, and the mean left ventricular ejection fraction (LVEF) was 67&#x000b1;8%. MR
grade was considered severe in 115 patients (92%) and moderate in the remaining 10
(8%).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demography.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="70%" span="1"/><col width="30%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">125</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at surgery - mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">57&#x000b1;15</td></tr><tr><td align="left" rowspan="1" colspan="1">Range, years</td><td align="center" rowspan="1" colspan="1">9 - 87</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male</td><td align="center" rowspan="1" colspan="1">52 (41.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Degenerative</td><td align="center" rowspan="1" colspan="1">73 (58.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Myxomatous
degeneration</td><td align="center" rowspan="1" colspan="1">57 (45.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fibroelastic
deficiency</td><td align="center" rowspan="1" colspan="1">9 (7.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Barlow syndrome</td><td align="center" rowspan="1" colspan="1">7 (5.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rheumatic</td><td align="center" rowspan="1" colspan="1">34 (27.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Congenital</td><td align="center" rowspan="1" colspan="1">5 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pure annular dilatation</td><td align="center" rowspan="1" colspan="1">3 (2.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Infective endocarditis</td><td align="center" rowspan="1" colspan="1">9 (7.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Healed</td><td align="center" rowspan="1" colspan="1">5 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Active</td><td align="center" rowspan="1" colspan="1">4 (3.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Endomyocardial fibrosis</td><td align="center" rowspan="1" colspan="1">1 (0.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA Class</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">23 (18.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">58 (46.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">36 (28.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">8 (6.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous cardiac operations</td><td align="center" rowspan="1" colspan="1">13 (10.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic arterial hypertension</td><td align="center" rowspan="1" colspan="1">59 (47.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">3 (2.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">8 (6.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">10 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal failure</td><td align="center" rowspan="1" colspan="1">8 (6.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1">9 (7.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation/Flutter</td><td align="center" rowspan="1" colspan="1">36 (28.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%) - mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">67&#x000b1;8.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">31-84</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Below 50%</td><td align="center" rowspan="1" colspan="1">5 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">DDLV (mm) - mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">55&#x000b1;7.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">41-76</td></tr><tr><td align="left" rowspan="1" colspan="1">SDLV (mm) - mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">34&#x000b1;6.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">25-56</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitral regurgitation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate</td><td align="center" rowspan="1" colspan="1">10 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe</td><td align="center" rowspan="1" colspan="1">115 (92%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tricuspid regurgitation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate</td><td align="center" rowspan="1" colspan="1">18 (14.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe</td><td align="center" rowspan="1" colspan="1">2 (1.6%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>DDLV=diastolic dimension of the left ventricle; LVEF=left ventricular
ejection fraction; NYHA=New York Heart Association; SD=standard
deviation; SDLV=systolic dimension of the left ventricle</p></fn></table-wrap-foot></table-wrap><p>Operative findings, repair techniques, and concomitant procedures are listed in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Operative data and surgical findings.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="70%" span="1"/><col width="30%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">125</td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Degenerative</td><td align="center" rowspan="1" colspan="1">73 (58.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Anterior prolapse</td><td align="center" rowspan="1" colspan="1">11 (15.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Posterior prolapse</td><td align="center" rowspan="1" colspan="1">49 (67.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Bileaflet prolapse</td><td align="center" rowspan="1" colspan="1">13 (17.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rheumatic</td><td align="center" rowspan="1" colspan="1">34 (27.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Congenital</td><td align="center" rowspan="1" colspan="1">5 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pure annular dilatation</td><td align="center" rowspan="1" colspan="1">3 (2.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Endomyocardial fibrosis</td><td align="center" rowspan="1" colspan="1">1 (0.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Active infective endocarditis</td><td align="center" rowspan="1" colspan="1">4 (3.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Healed infective endocarditis</td><td align="center" rowspan="1" colspan="1">5 (4.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Incision</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Median sternotomy</td><td align="center" rowspan="1" colspan="1">115 (92.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Right minithoracotomy</td><td align="center" rowspan="1" colspan="1">10 (8.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">No annuloplasty ring</td><td align="center" rowspan="1" colspan="1">11 (8.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitral annuloplasty ring</td><td align="center" rowspan="1" colspan="1">114 (91.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Carpentier-Edwards Physio II Ring</td><td align="center" rowspan="1" colspan="1">61 (48.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bovine Pericardial band</td><td align="center" rowspan="1" colspan="1">47 (37.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregori Ring 2</td><td align="center" rowspan="1" colspan="1">2 (1.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Carpentier Classic Ring</td><td align="center" rowspan="1" colspan="1">3 (2.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Braile 1</td><td align="center" rowspan="1" colspan="1">1 (0.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chordal replacement with Gore-Tex sutures</td><td align="center" rowspan="1" colspan="1">76 (60.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of pericardial patches</td><td align="center" rowspan="1" colspan="1">12 (9.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Triangular resection</td><td align="center" rowspan="1" colspan="1">20 (16.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Quadrangular resection</td><td align="center" rowspan="1" colspan="1">24 (19.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tricuspid valve surgery</td><td align="center" rowspan="1" colspan="1">20 (16.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery bypass graft</td><td align="center" rowspan="1" colspan="1">8 (6.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation ablation</td><td align="center" rowspan="1" colspan="1">18 (14.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB time (min) - mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">93&#x000b1;35</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">35 - 240</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic clamping time (min) - mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">73&#x000b1;29</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">23 - 197</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CPB=cardiopulmonary bypass; SD =standard deviation</p></fn></table-wrap-foot></table-wrap><p>The mean clinical follow-up was 3.7&#x000b1;3.4 years (range: 0.1 - 12.4 years), with
a total cumulative follow-up of 462.2 patientyears. In total, 697 echocardiograms
were available for analysis. The latest echocardiogram was performed after a mean of
3.1&#x000b1;2.9 years (range: 0.1 - 12.3 years).</p><sec><title>Early and Late Mortality</title><p>There were three early deaths with an overall early mortality of 2.4%. Among
patients younger than 70 years, early mortality was 0.9% (1/102). Causes of
early death were multi-organ failure in an 81-year-old patient with degenerative
disease and healed bacterial endocarditis, respiratory failure in a 77-year-old
patient with degenerative disease and low output syndrome in a rheumatic patient
that was submitted to concomitant myocardial revascularization and AF
ablation.</p><p>In addition, six patients died in the late postoperative period. Causes of late
death were sudden death (n = 2), congestive heart failure, intracranial
hemorrhage, hepatic cirrhosis, and unknown, in one case each. By Kaplan-Meier
analysis, estimated five and 10 years survival were 89.5% (CI 95% = 78.8% -
94.9%) and 84.3% (CI95% = 67.1% - 92.9%), respectively, which were similar to an
age- and gender-matched Brazilian population (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Late survival after mitral valve repair.</p></caption><graphic xlink:href="rbccv-33-01-0023-g01"/></fig>
</p><p>Risk factors for late mortality included age (HR = 3.30, CI95% = 0.85 - 12.7),
associated CAD (HR = 2.48, CI95% = 0.42 - 14.2), diabetes (HR = 7.85, CI95% =
0.49 - 123.4), longer aortic crossclamp (HR = 4.07, CI95% = 1.09 - 15.1), and
ECC times (HR=5.00, CI95% = 1.17-21.2) (<xref ref-type="app" rid="app1">Appendix
1</xref>).</p></sec><sec><title>Clinical Follow-up</title><p>Among the 111 survivors with known clinical status, 101 are in NYHA functional
class I, nine in class II and only one in class III. This latter patient,
despite a normally functioning mitral repair, developed moderate to severe
tricuspid regurgitation and should undergo reoperation in the near future.
During the observation period, five patients presented thromboembolic events,
three were transient ischemic attacks and two were strokes. Freedom from
thromboembolic events at five and 10 years was 93.1% (CI95% = 83.3% - 97.2%)
(<xref ref-type="fig" rid="f2">Figure 2</xref>). In addition, two patients
presented with serious hemorrhagic complications, which were the cause of death
in one. There were no documented cases of bacterial endocarditis.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Freedom from thromboembolic complications after mitral valve
repair.</p></caption><graphic xlink:href="rbccv-33-01-0023-g02"/></fig>
</p><p>By echocardiogram, late LVEF was 65.5&#x000b1;7.5% (range = 27 - 77), with only
three being below 50%. Late diastolic dimension of the left ventricle (DDLV) was
48&#x000b1;6 mm (range = 37 - 74) and systolic dimension of the left ventricle
(SDLV) was 31&#x000b1;6 mm (range = 22 - 68).</p></sec><sec><title>Reoperations and Mitral Valve Dysfunction</title><p>At discharge, only one patient had moderate MR with no further progression after
six years.</p><p>During follow-up, two patients developed severe MR and were reoperated. Mitral
valve could be re-repaired in both. Mechanisms of failure were dehiscence of the
posterior leaflet suture line in one case (technical failure) and progression of
the disease in another, with a new prolapse of the anterior leaflet. Freedom
from severe MR and/or reoperation was 95.6% (CI95% = 82.5% - 98.9%) at 5 and 10
years (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Freedom from severe mitral regurgitation (MR) after mitral valve
repair. Two patients developed this complication, and both were
reoperated.</p></caption><graphic xlink:href="rbccv-33-01-0023-g03"/></fig>
</p><p>Four additional patients developed moderate MR at late follow-up, but they are
asymptomatic and under careful observation. Freedom from valve failure (more
than mild MR or reoperation) was 88.2% (CI95% = 74.8% - 94.7%) at 5 years and
84.5% (CI95% = 68.8% - 92.6%) at 10 years. There was no difference in freedom
from valve failure between degenerative and rheumatic valves at 10 years (<xref ref-type="fig" rid="f4">Figure 4</xref>). Curiously, univariable analysis
revealed renal failure as the only risk factor for late mitral valve dysfunction
(HR = 9.31, CI95% = 0.22-397.66) (<xref ref-type="app" rid="app1">Appendix
1</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>A) Freedom from valve failure after mitral valve repair. Failure was
defined as any mitral regurgitation (MR) &#x02265; moderate or
reoperation due to any cause. B) Freedom from valve failure
stratified according to patients presenting with degenerative or
rheumatic disease.</p><p>MR=mitral regurgitation</p></caption><graphic xlink:href="rbccv-33-01-0023-g04"/></fig>
</p></sec><sec><title>Tricuspid Valve Function</title><p>Four patients (moderate = 3, severe = 1) with preoperative TR underwent
concomitant tricuspid annuloplasty during the operation. In addition, 16
patients with dilated tricuspid annulus, but with none or mild TR, also
underwent "prophylactic"tricuspid repair with a Carpentier Edwards Tricuspid
Physio ring<sup>&#x000ae;</sup>. None had more than mild TR at late follow-up. In
contrast, new moderate (n = 6) or severe TR (n = 1) was detected in patients in
whom the tricuspid valve was not addressed during the primary operation. Overall
freedom from &#x02265; moderate TR was 66.1% (CI95% = 37.1 - 84.2%) at 10 years.
Univariable analysis revealed RD as the only risk factor for development of late
TR (HR = 6.69 [CI95% = 1.69 - 40.09] - P=0.044) (<xref ref-type="fig" rid="f5">Figure 5</xref>, <xref ref-type="app" rid="app1">Appendix 1</xref>).</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>A) Freedom from late development of moderate or severe tricuspid
regurgitation (TR) after mitral valve repair. B) Freedom from late
development of moderate or severe tricuspid regurgitation (TR) after
mitral valve repair stratified according to patients presenting
degenerative or rheumatic disease.</p><p>MR=mitral regurgitation</p></caption><graphic xlink:href="rbccv-33-01-0023-g05"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This study demonstrates that it is possible to obtain high rates of MVR for patients
with organic MR, from different etiologies, in dedicated centers<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Our repair rate of 93.9% for all-comers includes not
only patients with degenerative disease, but also those with more challenging
rheumatic and acutely infected valves<sup>[<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]</sup>. This
aspect seems to be very relevant, at a time when the American College of Cardiology
(ACC) and other cardiological societies are making efforts to create high volume
regional reference centers that fulfill excellence criteria in the surgical
management of patients with MR. It is our opinion that in Brazil, where global
reparability rates are still very low, special programs such as specialized
fellowships and dedicated symposiums should be promoted for adequate training of
surgeons, clinicians, anesthesiologists and echocardiographists.</p><p>Several groups have documented excellent outcomes and a reparability rate ranging
from 95-100% for patients with degenerative disease<sup>[<xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r16" ref-type="bibr">16</xref>]</sup>. In the present series, 97.2% of degenerative
valves were treated in this manner, with very acceptable early mortality and low
incidence of residual regurgitation. The only two patients who had mitral valve
replacement were cases with previous repairs done elsewhere and which were judged as
suboptimal candidates for a second repair due to important scaring and distortion of
the valve apparatus.</p><p>On the other hand, rheumatic and/or infected valves may impose special challenges,
and reports about conservative surgical treatment in these situations have
demonstrated a much lower reparability rate<sup>[<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]</sup>.
We believe, however, that with proper surgical expertise and an aggressive approach,
it is possible to avoid valve replacement in a substantial number of cases in this
subset of patients.</p><p>Our overall early mortality of 2.4% was acceptable in view of the wide range of
pathologies treated and not limited to the more simple degenerative posterior mitral
valve prolapse<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.
Our three deaths occurred only in older patients with extensive degenerative disease
or in the presence of associated CAD. Mortality was 0% for patients with isolated
primary mitral valve surgery, with or without concomitant tricuspid or AF, under the
age of 70 years, which compares favorably with the STS database<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>A relevant finding of this study was the excellent long-term survival, that was
similar to the age- and sex-matched Brazilian population at least for the first
decade after operation. This reinforces our tendency for recommending early surgery
for patients with severe MR, even for asymptomatic patients, before they reach class
I guideline triggers for surgery, such as AF and pulmonary artery
hypertension<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Although some authors feel that a "watchful waiting"
policy is safe and reasonable for asymptomatic patients<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, recent studies have
demonstrated that long-term survival may be compromised with that
approach<sup>[<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>Not only survival, but also long-term functional results were very gratifying, with
most patients presenting normal functional recovery in NYHA class I and with low
incidence of valve related complications. Thromboembolic events were uncommon,
occurred more frequently during the first few years and had no relation with the
presence of AF. However, it must be emphasized that all patients with documented AF
were under anticoagulation therapy. Furthermore, 16 out of 18 patients who had AF
treated by bipolar radiofrequency are in sinus rhythm as demonstrated by regular
electrocardiograms and/or 24 hours Holter examination. It is also important that
there were no cases of bacterial endocarditis during the observation period, even in
patients that had acute or healed endocarditis as the primary reason for operation.
Although this study did not intend to compare MVR with mitral valve replacement, one
should expect a higher incidence of valve-related complications if these patients
have had replacement as the surgical procedure<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>One of the caveats of reconstructive mitral surgery is the possibility of recurrent
MR and eventual need for reoperations. The main reasons for recurrent MR are
technical failures, disease progression and scarring after the
repair<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.
In this study, because the incidence of recurrent severe MR was infrequent and the
number of patients was relatively small, statistical analysis had important
limitations for establishing risk factors associated with this complication. One
important finding, however, was that, at least up to ten years, results in rheumatic
patients were similar to those with degenerative disease. We have been very
aggressive in treating rheumatic pathologies, making extensive shaving of thickened
and retracted tissues, debridement of calcified areas, cutting secondary chords and
even performing partial and total primary chordal replacement to increase leaflet
mobility and to obtain adequate coaptation surface areas. In the presence of
retracted anterior leaflets, cusp extension with decellularized pericardium has been
an important maneuver for a satisfactory result<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. With that policy, the incidence of
recurrent moderate or severe MR has been low, although we often must accept smaller
final effective orifice areas (around 1.8 - 2.5 cm<sup>2</sup>) in patients with
mixed lesions. In our country, Severino et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> and Pomerantzeff et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> have also shown the
apparent feasibility and advantages of MVR in rheumatic patients. On the other hand,
it must be emphasized that most rheumatic patients in this study had the so-called
"burn-out" disease, that is less susceptible to newer acute inflammatory bursts of
rheumatic fever, besides being carefully oriented and controlled with lifelong
antibiotic prophylaxis against the disease<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Although still controversial, several recent reports have stressed the importance of
avoiding late tricuspid regurgitation after a successful mitral
operation<sup>[<xref rid="r26" ref-type="bibr">26</xref>-<xref rid="r29" ref-type="bibr">29</xref>]</sup>. It is becoming more
apparent that the concept that any degree of functional tricuspid regurgitation
would improve by correcting left-sided lesions only is misleading, and the
occurrence of moderate to severe TR and eventual need for reintervention is not
negligible<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. This is corroborated in the present series in which
approximately one third of the patients had more than mild TR late after the initial
operation when the tricuspid valve was not addressed, especially in rheumatic
patients. Furthemore, reoperations for isolated late TR after MVR carry a high
operative risk and thus should be avoided<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. In the initial phase of the present
series, we have repaired the tricuspid valve whenever we found moderate or severe TR
with symptoms of right side failure and visual right ventricular (RV) and right
atrial (RA) enlargement during the operation. More recently, however, we moved
towards a more aggressive approach on the tricuspid valve, and we performed
tricuspid annuloplasty not only in patients with moderate or severe functional TR
but also when dilatation of the tricuspid annulus was greater than 40 mm by
echocardiography<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>, as recommended by Chikwe et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> and Dreyfus et
al.<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>.
Although follow-up is still short, we have not identified a single late TR after
tricuspid annuloplasty with Carpentier-Edwards Tricuspid Physio ring.</p><p>This study has several limitations. All operations were performed by a single surgeon
and selection biases and individual approaches to certain pathologies may influence
outcomes, and the results may not be generalized. In the first years of this
experience, tricuspid valve annulus size and degree of regurgitation were not
evaluated in the same systematic manner as more recently, so underestimation of TR
may have occurred. Furthermore, because TR is not a terminal event and longitudinal
echocardiography data are not complete, any conclusion regarding the true incidence
of more than mild TR should be done with caution. Some echocardiography data
regarding late function of the mitral and tricuspid valves were obtained outside our
clinic and may cause some inconsistencies.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, we have demonstrated that MR due to organic mitral valve disease, from
various etiologies, can be surgically treated with a high repair rate, low early
mortality and long-term survival that are comparable to the matched general
population. Concomitant treatment of AF and tricuspid valve may be important
adjuncts to optimize long-term results. In our opinion, however, this can only be
accomplished in reference centers with a dedicated heart valve team working in a
focused and systematic way in order to obtain consistent results.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FDAC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DFFC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLSM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KCSP</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MCB</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EMBF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MV</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ADAF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Instituto de Neurologia e Cardiologia de Curitiba
(INC-Cardio), Curitiba, PR, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><app-group><app id="app1"><label>Appendix 1.</label><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="30%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Risk factors for mitral valve dysfunction</th><th align="center" rowspan="1" colspan="1">Hazard ratio (95%CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">0.455 (0.085 to 2.423)</td><td align="center" rowspan="1" colspan="1">0.453</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">0.259 (0.056 to 1.182)</td><td align="center" rowspan="1" colspan="1">0.177</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA functional class</td><td align="center" rowspan="1" colspan="1">1.856 (0.413 to 8.337)</td><td align="center" rowspan="1" colspan="1">0.409</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">1.024 (0.197 to 5.329)</td><td align="center" rowspan="1" colspan="1">0.976</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic arterial hypertension</td><td align="center" rowspan="1" colspan="1">1.571 (0.355 to 6.950)</td><td align="center" rowspan="1" colspan="1">0.549</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.624</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">3.121 (0.106 to 91.445)</td><td align="center" rowspan="1" colspan="1">0.265</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">2.121 (0.122 to 36.685)</td><td align="center" rowspan="1" colspan="1">0.475</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal failure</td><td align="center" rowspan="1" colspan="1">9.315 (0.223 to 387.661)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous cardiac operations</td><td align="center" rowspan="1" colspan="1">3.357 (0.303 to 37.079)</td><td align="center" rowspan="1" colspan="1">0.123</td></tr><tr><td align="left" rowspan="1" colspan="1">Associated surgical procedures</td><td align="center" rowspan="1" colspan="1">1.939 (0.371 to 10.118)</td><td align="center" rowspan="1" colspan="1">0.375</td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology</td><td align="center" rowspan="1" colspan="1">2.033 (0.382 to 10.798)</td><td align="center" rowspan="1" colspan="1">0.342</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time</td><td align="center" rowspan="1" colspan="1">0.959 (0.188 to 4.873)</td><td align="center" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic clamping time</td><td align="center" rowspan="1" colspan="1">0.732 (0.155 to 3.451)</td><td align="center" rowspan="1" colspan="1">0.705</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CI=confidence interval; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="30%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Risk factors for mortality</th><th align="center" rowspan="1" colspan="1">Hazard ratio (95%CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">3.301 (0.857 to 12.709)</td><td align="center" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">1.979 (0.535 to 7.312)</td><td align="center" rowspan="1" colspan="1">0.290</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class</td><td align="center" rowspan="1" colspan="1">1.552 (0.390 to 6.163)</td><td align="center" rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">0.871 (0.224 to 3.384)</td><td align="center" rowspan="1" colspan="1">0.824</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic arterial hypertension</td><td align="center" rowspan="1" colspan="1">1.753 (0.473 to 6.495)</td><td align="center" rowspan="1" colspan="1">0.391</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">7.855 (0.499 to 123.422)</td><td align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">0.563 (0.103 to 3.065)</td><td align="center" rowspan="1" colspan="1">0.404</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal failure</td><td align="center" rowspan="1" colspan="1">2.546 (0.115 to 56.145)</td><td align="center" rowspan="1" colspan="1">0.356</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1">2.485 (0.432 to 14.295)</td><td align="center" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous cardiac operations</td><td align="center" rowspan="1" colspan="1">3.647 (0.294 to 45.196)</td><td align="center" rowspan="1" colspan="1">0.079</td></tr><tr><td align="left" rowspan="1" colspan="1">Associated surgical procedures</td><td align="center" rowspan="1" colspan="1">1.863 (0.491 to 7.065)</td><td align="center" rowspan="1" colspan="1">0.292</td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology</td><td align="center" rowspan="1" colspan="1">0.430 (0.090 to 2.055)</td><td align="center" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time</td><td align="center" rowspan="1" colspan="1">5.002 (1.177 to 21.245)</td><td align="center" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic clamping time</td><td align="center" rowspan="1" colspan="1">4.076 (1.099 to 15.115)</td><td align="center" rowspan="1" colspan="1">0.034</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CI=confidence interval; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="30%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Risk factors for tricuspid valve dysfunction</th><th align="center" rowspan="1" colspan="1">Hazard ratio (95%CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.120 (0.115 to 10.844)</td><td align="center" rowspan="1" colspan="1">0.918</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class</td><td align="center" rowspan="1" colspan="1">2.422 (0.398 to 14.705)</td><td align="center" rowspan="1" colspan="1">0.307</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">1.749 (0.246 to 12.431)</td><td align="center" rowspan="1" colspan="1">0.530</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic arterial hypertension</td><td align="center" rowspan="1" colspan="1">4.339 (0.750 to 25.085)</td><td align="center" rowspan="1" colspan="1">0.150</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">NaN</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.622</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.734</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.773</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.872</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous cardiac operations</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.455</td></tr><tr><td align="left" rowspan="1" colspan="1">Associated surgical procedures</td><td align="center" rowspan="1" colspan="1">0.730 (0.097 to 5.454)</td><td align="center" rowspan="1" colspan="1">0.776</td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology</td><td align="center" rowspan="1" colspan="1">6.698 (1.094 to 40.998)</td><td align="center" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.321</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic clamping time</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.287</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>CI=confidence interval; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap></app></app-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazam</surname><given-names>S</given-names></name><name><surname>Vanoverschelde</surname><given-names>JL</given-names></name><name><surname>Tribouilloy</surname><given-names>C</given-names></name><name><surname>Grigioni</surname><given-names>F</given-names></name><name><surname>Suri</surname><given-names>RM</given-names></name><name><surname>Avierinos</surname><given-names>JF</given-names></name><etal/><collab>MIDA (Mitral Regurgitation International Database)
Investigators</collab></person-group><article-title>Twenty-year outcome after mitral repair versus replacement for
severe degenerative mitral regurgitation: analysis of a large, prospective,
multicenter, international registry</article-title><source>Circulation</source><year>2017</year><volume>135</volume><issue>5</issue><fpage>410</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">27899396</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chikwe</surname><given-names>J</given-names></name><name><surname>Goldstone</surname><given-names>AB</given-names></name><name><surname>Passage</surname><given-names>J</given-names></name><name><surname>Anyanwu</surname><given-names>AC</given-names></name><name><surname>Seeburger</surname><given-names>J</given-names></name><name><surname>Castillo</surname><given-names>JG</given-names></name><etal/></person-group><article-title>A propensity score-adjusted retrospective comparison of early and
mid-term results of mitral valve repair versus replacement in
octogenarians</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>5</issue><fpage>618</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">20846993</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>JP 3rd</surname><given-names>Erwin</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><etal/><collab>American College of Cardiology</collab><collab>American Heart Association Task Force on Practice
Guidelines</collab></person-group><article-title>2014 AHA/ACC guideline for the management of patients with
valvular heart disease: executive summary: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><issue>22</issue><fpage>2438</fpage><lpage>2488</lpage><pub-id pub-id-type="pmid">24603192</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Joint Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology (ESC)</collab><collab>European Association for Cardio-Thoracic (EACTS)</collab><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Alfieri</surname><given-names>O</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><name><surname>Bar&#x000f3;n-Esquivias</surname><given-names>G</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><etal/></person-group><article-title>Guidelines on the management of valvular heart disease (version
2012)</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>19</issue><fpage>2451</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">22922415</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammie</surname><given-names>JS</given-names></name><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>Griffith</surname><given-names>BP</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Rankin</surname><given-names>JS</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Trends in mitral valve surgery in the United States: results from
the Society of Thoracic Surgeons Adult Cardiac Surgery
Database</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>87</volume><issue>5</issue><fpage>1431</fpage><lpage>1437</lpage><pub-id pub-id-type="pmid">19379881</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmunds Jr</surname><given-names>LH</given-names></name><name><surname>Cohn</surname><given-names>LH</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name></person-group><article-title>Guidelines for reporting morbidity and mortality after cardiac
valvular operations</article-title><source>J Thorac Cardiovasc Surg</source><year>1988</year><volume>96</volume><issue>3</issue><fpage>351</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">3411979</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>WA</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Grayburn</surname><given-names>PA</given-names></name><name><surname>Kraft</surname><given-names>CD</given-names></name><name><surname>Levine</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Recommendations for evaluation of the severity of native valvular
regurgitation with two-dimensional and Doppler
echocardiography</article-title><source>J Am Soc Echocardiogr</source><year>2003</year><volume>16</volume><issue>7</issue><fpage>777</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">12835667</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>JG</given-names></name><name><surname>Anyanwu</surname><given-names>AC</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>A near 100% repair rate for mitral valve prolapse is achievable
in a reference center: implications for future guidelines</article-title><source>J Thorac Cardiovasc Surg</source><year>2012</year><volume>144</volume><issue>2</issue><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">22698565</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>TE</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>McCrindle</surname><given-names>BW</given-names></name><name><surname>Manlhiot</surname><given-names>C</given-names></name></person-group><article-title>Late outcomes of mitral valve repair for mitral regurgitation due
to degenerative disease</article-title><source>Circulation</source><year>2013</year><volume>127</volume><issue>14</issue><fpage>1485</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">23459614</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanemitsu</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Fukunaga</surname><given-names>N</given-names></name><name><surname>Koyama</surname><given-names>T</given-names></name></person-group><article-title>Long-term outcomes of mitral valve repair for active
endocarditis</article-title><source>Circ J</source><year>2016</year><volume>80</volume><issue>5</issue><fpage>1148</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">27039946</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillon</surname><given-names>J</given-names></name><name><surname>Yakub</surname><given-names>MA</given-names></name><name><surname>Kong</surname><given-names>PK</given-names></name><name><surname>Ramli</surname><given-names>MF</given-names></name><name><surname>Jaffar</surname><given-names>N</given-names></name><name><surname>Gaffar</surname><given-names>IF</given-names></name></person-group><article-title>Comparative long-term results of mitral valve repair in adults
with chronic rheumatic disease and degenerative disease: is repair for
"burnt-out" rheumatic disease still inferior to repair for degenerative
disease in the current era?</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>149</volume><issue>3</issue><fpage>771</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">25308120</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>The Time has come to define centers of excellence in mitral valve
repair</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>67</volume><issue>5</issue><fpage>499</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">26846947</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>JG</given-names></name><name><surname>Anyanwu</surname><given-names>AC</given-names></name><name><surname>El-Eshmawi</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>All anterior and bileaflet mitral valve prolapses are repairable
in the modern era of reconstructive surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2014</year><volume>45</volume><issue>1</issue><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">23625450</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>TE</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>Ivanov</surname><given-names>J</given-names></name></person-group><article-title>Chordal replacement with polytetrafluoroethylene sutures for
mitral valve repair: a 25-year experience</article-title><source>J Thorac Cardiovasc Surg</source><year>2013</year><volume>145</volume><issue>6</issue><fpage>1563</fpage><lpage>1569</lpage><pub-id pub-id-type="pmid">22713304</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koprivanac</surname><given-names>M</given-names></name><name><surname>Kelava</surname><given-names>M</given-names></name><name><surname>Alansari</surname><given-names>S</given-names></name><name><surname>Javadikasgari</surname><given-names>H</given-names></name><name><surname>Tappuni</surname><given-names>B</given-names></name><name><surname>Mick</surname><given-names>S</given-names></name><etal/></person-group><article-title>Degenerative mitral valve disease-contemporary surgical
approaches and repair techniques</article-title><source>Ann Cardiothorac Surg</source><year>2017</year><volume>6</volume><issue>1</issue><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">28203540</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand&#x000e3;o</surname><given-names>CM</given-names></name><name><surname>Guedes</surname><given-names>MA</given-names></name><name><surname>Silva</surname><given-names>MF</given-names></name><name><surname>Vieira</surname><given-names>ML</given-names></name><name><surname>Pomerantzeff</surname><given-names>PM</given-names></name><name><surname>Stolf</surname><given-names>NA</given-names></name></person-group><article-title>Mitral valve repair with "Double Teflon" technique: 10-year
results.</article-title><source>Rev Bras Cir Cardiovasc</source><year>2007</year><volume>22</volume><issue>4</issue><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">18488112</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Suri</surname><given-names>RM</given-names></name><name><surname>Clavel</surname><given-names>MA</given-names></name><name><surname>Mantovani</surname><given-names>F</given-names></name><name><surname>Michelena</surname><given-names>HI</given-names></name><name><surname>Pislaru</surname><given-names>S</given-names></name><etal/></person-group><article-title>Is there an outcome penalty linked to guideline-based indications
for valvular surgery? Early and long-term analysis of patients with organic
mitral regurgitation</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>150</volume><issue>1</issue><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">25986494</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenhek</surname><given-names>R</given-names></name></person-group><article-title>Watchful waiting for severe mitral regurgitation</article-title><source>Semin Thorac Cardiovasc Surg</source><year>2011</year><volume>23</volume><issue>3</issue><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">22172357</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazdchi</surname><given-names>F</given-names></name><name><surname>Koch</surname><given-names>CG</given-names></name><name><surname>Mihaljevic</surname><given-names>T</given-names></name><name><surname>Hachamovitch</surname><given-names>R</given-names></name><name><surname>Lowry</surname><given-names>AM</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal/></person-group><article-title>Increasing disadvantage of "watchful waiting" for repairing
degenerative mitral valve disease</article-title><source>Ann Thorac Surg</source><year>2015</year><volume>99</volume><issue>6</issue><fpage>1992</fpage><lpage>2000</lpage><pub-id pub-id-type="pmid">25916875</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suri</surname><given-names>RM</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name></person-group><article-title>Better to avoid disaster than rescue defeat: ventricular
dysfunction after delayed mitral valve repair</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>149</volume><issue>3</issue><fpage>941</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">25827381</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javadikasgari</surname><given-names>H</given-names></name><name><surname>Gillinov</surname><given-names>AM</given-names></name><name><surname>Idrees</surname><given-names>JJ</given-names></name><name><surname>Mihaljevic</surname><given-names>T</given-names></name><name><surname>Suri</surname><given-names>RM</given-names></name><name><surname>Raza</surname><given-names>S</given-names></name><etal/></person-group><article-title>Valve repair is superior to replacement in most patients with
coexisting degenerative mitral valve and coronary artery
diseases</article-title><source>Ann Thorac Surg</source><year>2017</year><volume>103</volume><issue>6</issue><fpage>1833</fpage><lpage>1841</lpage><pub-id pub-id-type="pmid">27938885</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suri</surname><given-names>RM</given-names></name><name><surname>Clavel</surname><given-names>MA</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Michelena</surname><given-names>HI</given-names></name><name><surname>Huebner</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Effect of recurrent mitral regurgitation following degenerative
mitral valve repair: long-term analysis of competing
outcomes</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>67</volume><issue>5</issue><fpage>488</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">26846946</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillon</surname><given-names>J</given-names></name><name><surname>Yakub</surname><given-names>MA</given-names></name><name><surname>Pau</surname><given-names>KK</given-names></name><name><surname>Taib</surname><given-names>ME.</given-names></name></person-group><article-title>Leaflet extension for repairing rheumatic mitral valve
regurgitation</article-title><source>Ann Cardiothorac Surg</source><year>2015</year><volume>4</volume><issue>3</issue><fpage>301</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">26309837</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severino</surname><given-names>ES</given-names></name><name><surname>Petrucci</surname><given-names>O</given-names></name><name><surname>Vilarinho</surname><given-names>KA</given-names></name><name><surname>Lavagnoli</surname><given-names>CF</given-names></name><name><surname>Silveira Filho</surname><given-names>LM</given-names></name><name><surname>Oliveira</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Late outcomes of mitral repair in rheumatic
patients</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>4</issue><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">22358270</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomerantzeff</surname><given-names>PM</given-names></name><name><surname>Brand&#x000e3;o</surname><given-names>CM</given-names></name><name><surname>Leite Filho</surname><given-names>OA</given-names></name><name><surname>Guedes</surname><given-names>MA</given-names></name><name><surname>Silva</surname><given-names>MF</given-names></name><name><surname>Grinberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mitral valve repair in rheumatic patients with mitral
insuficiency: twenty years of techniques and results</article-title><source>Rev Bras Cir Cardiovasc</source><year>2009</year><volume>24</volume><issue>4</issue><fpage>485</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">20305921</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chikwe</surname><given-names>J</given-names></name><name><surname>Itagaki</surname><given-names>S</given-names></name><name><surname>Anyanwu</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>Impact of concomitant tricuspid annuloplasty on tricuspid
regurgitation, right ventricular function, and pulmonary artery hypertension
after repair of mitral valve prolapse</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>65</volume><issue>18</issue><fpage>1931</fpage><lpage>1938</lpage><pub-id pub-id-type="pmid">25936265</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filsoufi</surname><given-names>F</given-names></name><name><surname>Chikwe</surname><given-names>J</given-names></name><name><surname>Carpentier</surname><given-names>A</given-names></name></person-group><article-title>Rationale for remodelling annuloplasty to address functional
tricuspid regurgitation during left-sided valve surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2015</year><volume>47</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">24944330</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyfus</surname><given-names>GD</given-names></name><name><surname>Martin</surname><given-names>RP</given-names></name><name><surname>Chan</surname><given-names>KM</given-names></name><name><surname>Dulguerov</surname><given-names>F</given-names></name><name><surname>Alexandrescu</surname><given-names>C</given-names></name></person-group><article-title>Functional tricuspid regurgitation: a need to revise our
understanding</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>65</volume><issue>21</issue><fpage>2331</fpage><lpage>2336</lpage><pub-id pub-id-type="pmid">26022823</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dion</surname><given-names>RA</given-names></name></person-group><article-title>Is the air in Toronto, Rochester, and Cleveland different from
that in London, Monaco, Leiden, Genk, Milan, and New York?</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>150</volume><issue>5</issue><fpage>1040</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">26410006</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>SG</given-names></name><name><surname>Dreyfus</surname><given-names>GD</given-names></name></person-group><article-title>Surgery for functional tricuspid regurgitation: current
techniques, outcomes and emerging concepts</article-title><source>Expert Rev Cardiovasc Ther</source><year>2009</year><volume>7</volume><issue>1</issue><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">19105769</pub-id></element-citation></ref></ref-list></back></article>